Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients

Not Applicable

Completed

Conditions: Burns

Interventions: Drug: Unfractionated heparin 5000 U q8 hours
Drug: Enoxaparin 40 mg q24 hours
Drug: Enoxaparin 30 mg q12 hours

First Posted Date: 2022-02-14

Last Posted Date: 2022-12-20

Lead Sponsor: King Abdullah International Medical Research Center

Target Recruit Count: 20

Registration Number: NCT05237726

Locations: 🇸🇦
King Abdulaziz Medical City, Riyadh, Saudi Arabia

Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment

Completed

Conditions: Fertilization in Vitro
Infertility, Female
Thrombophilia

Interventions: Drug: Enoxaparin

First Posted Date: 2022-02-04

Last Posted Date: 2022-09-10

Lead Sponsor: Faculdade de Medicina do ABC

Target Recruit Count: 104

Registration Number: NCT05225155

Locations: 🇧🇷
Assistencia Materno Infantil Lambert, Santo Andre, SP, Brazil

Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.

Completed

Conditions: COVID-19
Critical Illness
Anticoagulants and Bleeding Disorders
Deep Vein Thrombosis

Interventions: Drug: Enoxaparin
Drug: Heparin

First Posted Date: 2022-02-04

Last Posted Date: 2023-05-11

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 813

Registration Number: NCT05224388

Locations: 🇧🇪
Ghent University Hospital, Gent, Belgium

Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

Phase 2

Conditions: Prevention of Venous Thrombosis After TKA

Interventions: Drug: SHR2285 tablet
Drug: Enoxaparin

First Posted Date: 2022-01-24

Last Posted Date: 2022-03-21

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 500

Registration Number: NCT05203705

Locations: 🇨🇳
Perking Union Medical College Hospital, Beijing, Beijing, China

Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

Phase 3

Completed

Conditions: COVID-19
Venous Thromboembolism

Interventions: Drug: Dimolegin
Drug: Clexane

First Posted Date: 2022-01-11

Last Posted Date: 2022-01-11

Lead Sponsor: PharmaDiall Ltd.

Target Recruit Count: 399

Registration Number: NCT05185804

Locations: 🇷🇺
State Budgetary Institution of Healthcare Research Institute - Regional Clinical Hospital No. 1 named after Professor S.V. Ochapov Ministry of Health of the Krasnodar Territory, Krasnodar, Russian Federation
🇷🇺
Regional budgetary healthcare institution Ivanovskaya clinical hospital named after Kuvaevs, Ivanovo, Russian Federation
🇷🇺
St. Petersburg State Budgetary Healthcare Institution City Hospital No. 40 of Kurortny District, Sestroretsk, Russian Federation

and more 3 locations

Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE

Phase 3

Terminated

Conditions: Right Ventricular Dysfunction
Pulmonary Embolism
Pulmonary Thromboembolisms
Embolism, Pulmonary

Interventions: Procedure: Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)
Drug: Enoxaparin

First Posted Date: 2021-12-29

Last Posted Date: 2021-12-29

Lead Sponsor: Rajaie Cardiovascular Medical and Research Center

Target Recruit Count: 94

Registration Number: NCT05172115

Locations: 🇮🇷
Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, Islamic Republic of

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

Completed

Conditions: Deep Vein Thrombosis, Pulmonary Embolus

Interventions: Drug: Enoxaparin
Drug: Rivaroxaban

First Posted Date: 2021-10-19

Last Posted Date: 2023-07-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 89215

Registration Number: NCT05083455

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures

Phase 4

Terminated

Conditions: Venous Thrombosis Deep (Limbs)
Surgical Blood Loss

Interventions: Drug: Enoxaparin Injectable Product
Drug: Sodium chloride

First Posted Date: 2021-10-18

Last Posted Date: 2024-04-24

Lead Sponsor: Valleywise Health

Target Recruit Count: 6

Registration Number: NCT05081375

Locations: 🇺🇸
Valleywise Health, Phoenix, Arizona, United States

Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin

Phase 3

Conditions: Cancer
Rivaroxaban
Thromboprophylaxis
Venous Thromboembolism

Interventions: Drug: Rivaroxaban
Drug: Enoxaparin

First Posted Date: 2021-08-10

Last Posted Date: 2021-08-10

Lead Sponsor: André Luiz Malavasi Longo de Oliveira

Target Recruit Count: 440

Registration Number: NCT04999176

Locations: 🇧🇷
Science Valley Research Institute, Santo André, São Paulo, Brazil

Catheter-Related Early Thromboprophylaxis with Enoxaparin Studies

Phase 2

Recruiting

Conditions: Deep Venous Thrombosis

Interventions: Drug: Enoxaparin

First Posted Date: 2021-06-11

Last Posted Date: 2025-03-17

Lead Sponsor: Yale University

Target Recruit Count: 258

Registration Number: NCT04924322

Locations: 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy